The mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism

Sandeep K. Talapatra, Nahoum Guillaume Hsuan Anthony, Simon MacKay, Frank Kozielski

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Development of drug resistance during cancer chemotherapy is one of the major causes of chemotherapeutic failure for the majority of clinical agents. The aim of this study was to investigate the underlying molecular mechanism of resistance developed by the mitotic kinesin Eg5 against the potent second-generation ispinesib analogue SB743921 (1), a phase I/II clinical candidate. Biochemical and biophysical data demonstrate that point mutations in the inhibitor-binding pocket decrease the efficacy of 1 by several 1000-fold. Surprisingly, the structures of wild type and mutant Eg5 in complex with 1 display no apparent structural changes in the binding configuration of the drug candidate. Furthermore, ITC and modelling approaches reveal that resistance to 1 is not through conventional steric effects at the binding site, but through reduced flexibility and changes in energy fluctuation pathways through the protein that influence its function. This is a phenomenon we have called 'resistance by allostery'.

LanguageEnglish
Pages6317-6329
Number of pages13
JournalJournal of Medicinal Chemistry
Volume56
Issue number16
Early online date22 Jul 2013
DOIs
Publication statusPublished - 22 Aug 2013

Fingerprint

Kinesin
Point Mutation
Drug Resistance
Binding Sites
Drug Therapy
Pharmaceutical Preparations
Neoplasms
Proteins
ispinesib
SB 743921

Keywords

  • drug resistance
  • cancer chemotherapy
  • chemotherapeutic failure
  • molecular mechanism of resistance
  • mitotic kinesin Eg5
  • second-generation ispinesib analogue SB743921
  • phase I/II clinical candidate
  • allosteric resistance mechanism

Cite this

Talapatra, Sandeep K. ; Anthony, Nahoum Guillaume Hsuan ; MacKay, Simon ; Kozielski, Frank. / The mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. In: Journal of Medicinal Chemistry. 2013 ; Vol. 56, No. 16. pp. 6317-6329.
@article{7c32e1c8aefd49e6b9dec91f95c51f26,
title = "The mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism",
abstract = "Development of drug resistance during cancer chemotherapy is one of the major causes of chemotherapeutic failure for the majority of clinical agents. The aim of this study was to investigate the underlying molecular mechanism of resistance developed by the mitotic kinesin Eg5 against the potent second-generation ispinesib analogue SB743921 (1), a phase I/II clinical candidate. Biochemical and biophysical data demonstrate that point mutations in the inhibitor-binding pocket decrease the efficacy of 1 by several 1000-fold. Surprisingly, the structures of wild type and mutant Eg5 in complex with 1 display no apparent structural changes in the binding configuration of the drug candidate. Furthermore, ITC and modelling approaches reveal that resistance to 1 is not through conventional steric effects at the binding site, but through reduced flexibility and changes in energy fluctuation pathways through the protein that influence its function. This is a phenomenon we have called 'resistance by allostery'.",
keywords = "drug resistance, cancer chemotherapy, chemotherapeutic failure, molecular mechanism of resistance, mitotic kinesin Eg5, second-generation ispinesib analogue SB743921, phase I/II clinical candidate, allosteric resistance mechanism",
author = "Talapatra, {Sandeep K.} and Anthony, {Nahoum Guillaume Hsuan} and Simon MacKay and Frank Kozielski",
year = "2013",
month = "8",
day = "22",
doi = "10.1021/jm4006274",
language = "English",
volume = "56",
pages = "6317--6329",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "16",

}

The mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. / Talapatra, Sandeep K.; Anthony, Nahoum Guillaume Hsuan; MacKay, Simon; Kozielski, Frank.

In: Journal of Medicinal Chemistry, Vol. 56, No. 16, 22.08.2013, p. 6317-6329.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism

AU - Talapatra, Sandeep K.

AU - Anthony, Nahoum Guillaume Hsuan

AU - MacKay, Simon

AU - Kozielski, Frank

PY - 2013/8/22

Y1 - 2013/8/22

N2 - Development of drug resistance during cancer chemotherapy is one of the major causes of chemotherapeutic failure for the majority of clinical agents. The aim of this study was to investigate the underlying molecular mechanism of resistance developed by the mitotic kinesin Eg5 against the potent second-generation ispinesib analogue SB743921 (1), a phase I/II clinical candidate. Biochemical and biophysical data demonstrate that point mutations in the inhibitor-binding pocket decrease the efficacy of 1 by several 1000-fold. Surprisingly, the structures of wild type and mutant Eg5 in complex with 1 display no apparent structural changes in the binding configuration of the drug candidate. Furthermore, ITC and modelling approaches reveal that resistance to 1 is not through conventional steric effects at the binding site, but through reduced flexibility and changes in energy fluctuation pathways through the protein that influence its function. This is a phenomenon we have called 'resistance by allostery'.

AB - Development of drug resistance during cancer chemotherapy is one of the major causes of chemotherapeutic failure for the majority of clinical agents. The aim of this study was to investigate the underlying molecular mechanism of resistance developed by the mitotic kinesin Eg5 against the potent second-generation ispinesib analogue SB743921 (1), a phase I/II clinical candidate. Biochemical and biophysical data demonstrate that point mutations in the inhibitor-binding pocket decrease the efficacy of 1 by several 1000-fold. Surprisingly, the structures of wild type and mutant Eg5 in complex with 1 display no apparent structural changes in the binding configuration of the drug candidate. Furthermore, ITC and modelling approaches reveal that resistance to 1 is not through conventional steric effects at the binding site, but through reduced flexibility and changes in energy fluctuation pathways through the protein that influence its function. This is a phenomenon we have called 'resistance by allostery'.

KW - drug resistance

KW - cancer chemotherapy

KW - chemotherapeutic failure

KW - molecular mechanism of resistance

KW - mitotic kinesin Eg5

KW - second-generation ispinesib analogue SB743921

KW - phase I/II clinical candidate

KW - allosteric resistance mechanism

UR - http://pubs.acs.org/journal/jmcmar

U2 - 10.1021/jm4006274

DO - 10.1021/jm4006274

M3 - Article

VL - 56

SP - 6317

EP - 6329

JO - Journal of Medicinal Chemistry

T2 - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 16

ER -